Huichao X, Xiaoyu H, Bao L, Yongfeng C, Haoran N, Tong Y, Shimei Y, Shuxin G, Yutong Z, Tianzhi Y, Yan K, Keda ZandPingtian
Easy to use and store
Accelerated regulatory pathways for innovative medicines and the growing presence of regional biotechnology companies are strengthening the country's position as a major GLP-1 research and production hub
Why Choose THE RE/ CLINIC in Sandy, UT
This white paper identifies six GLP-1 trends for the upcoming year and corresponding takeaways for employers looking to craft a proactive utilization and care management approach
Roughly 1 in 8 adults have used a prescription glucagon-like peptide-1 agonist (GLP-1) to treat obesity, Type 2 diabetes, or another health condition, according to a KFF survey